HBM Healthcare Investments

Type

Venture Capital

Status

Active

Location

Zug, Switzerland

Total investments

243

Average round size

44M

Portfolio companies

127

Rounds per year

10.57

Lead investments

31

Follow on index

0.47

Exits

58

Stages of investment
Private EquityLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

The main office of represented VC is situated in the Zug. The company was established in Europe in Switzerland.

Among the most popular portfolio startups of the fund, we may highlight ARMO BioSciences, Harmony Biosciences, Vivoryon Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Medical, Medical Device. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Besides them, we counted 4 critical employees of this fund in our database.

The top activity for fund was in 2007. Despite it in 2019 the fund had an activity. The typical startup value when the investment from HBM Healthcare Investments AG is 100-500 millions dollars. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this HBM Healthcare Investments AG performs on 3 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the HBM Healthcare Investments AG, startups are often financed by OrbiMed, Kleiner Perkins, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Novartis Venture Fund, Venrock. In the next rounds fund is usually obtained by SV Health Investors, Alta Partners, Maverick Ventures.

Show more

Investor highlights

Industry focus
MedtechBiotech/Life Sciences
Stage focus
Series CSeries DSeries FSeries E
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 51 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
243
Lead investments
31
Exits
58
Rounds per year
10.57
Follow on index
0.47
Investments by industry
  • Biotechnology (180)
  • Health Care (155)
  • Medical (102)
  • Pharmaceutical (69)
  • Therapeutics (56)
  • Show 38 more
Investments by region
  • United States (149)
  • China (9)
  • Switzerland (17)
  • Denmark (4)
  • Germany (19)
  • Show 13 more
Peak activity year
2020
Number of Unicorns
3
Number of Decacorns
3
Number of Minotaurs
4

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
79M
Group Appearance index
0.75
Avg. company exit year
10
Avg. multiplicator
2.08
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Karius 02 May 2024 Biotechnology, Information Technology, Genetics, Life Science Late Stage Venture 100M United States, California, Redwood City
Sphingotec GmbH 19 Jul 2022 Biotechnology Early Stage Venture Brandenburg, Hohen Neuendorf, Germany

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.